These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34217060)

  • 1. Discovery of novel nitrogenous heterocyclic-containing quinoxaline-1,4-di-N-oxides as potent activator of autophagy in M.tb-infected macrophages.
    Zhang H; Lu Q; Zhang J; Qu W; Xie S; Huang L; Yuan Z; Pan Y
    Eur J Med Chem; 2021 Nov; 223():113657. PubMed ID: 34217060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, 3D-QSAR analysis and biological evaluation of quinoxaline 1,4-di-N-oxide derivatives as antituberculosis agents.
    Pan Y; Li P; Xie S; Tao Y; Chen D; Dai M; Hao H; Huang L; Wang Y; Wang L; Liu Z; Yuan Z
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4146-53. PubMed ID: 27426298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives.
    Moreno E; Ancizu S; Pérez-Silanes S; Torres E; Aldana I; Monge A
    Eur J Med Chem; 2010 Oct; 45(10):4418-26. PubMed ID: 20656380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives.
    Zarranz B; Jaso A; Aldana I; Monge A
    Bioorg Med Chem; 2003 May; 11(10):2149-56. PubMed ID: 12713824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
    Chopra S; Koolpe GA; Tambo-Ong AA; Matsuyama KN; Ryan KJ; Tran TB; Doppalapudi RS; Riccio ES; Iyer LV; Green CE; Wan B; Franzblau SG; Madrid PB
    J Med Chem; 2012 Jul; 55(13):6047-60. PubMed ID: 22691154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.
    Villar R; Vicente E; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
    J Antimicrob Chemother; 2008 Sep; 62(3):547-54. PubMed ID: 18502817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and preliminary in vitro evaluation of antimycobacterial activity of new pyrrolo[1,2-a] quinoxaline-carboxylic acid hydrazide derivatives.
    Guillon J; Reynolds RC; Leger JM; Guie MA; Massip S; Dallemagne P; Jarry C
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):489-95. PubMed ID: 15662953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents.
    Wu Y; Cheung CY; Zhou Y; Wang Z; Tu Z; Cook GM; Lu X
    Bioorg Med Chem; 2021 Nov; 49():116426. PubMed ID: 34624820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide.
    Ortega MA; Sainz Y; Montoya ME; Jaso A; Zarranz B; Aldana I; Monge A
    Arzneimittelforschung; 2002; 52(2):113-9. PubMed ID: 11878199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 1,2,3-triazole based quinoxaline-1,4-di-N-oxide derivatives as potential anti-tubercular agents.
    Srinivasarao S; Nandikolla A; Suresh A; Ewa AK; Głogowska A; Ghosh B; Kumar BK; Murugesan S; Pulya S; Aggarwal H; Sekhar KVGC
    Bioorg Chem; 2020 Jul; 100():103955. PubMed ID: 32464405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents.
    Jaso A; Zarranz B; Aldana I; Monge A
    J Med Chem; 2005 Mar; 48(6):2019-25. PubMed ID: 15771444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.
    Santivañez-Veliz M; Pérez-Silanes S; Torres E; Moreno-Viguri E
    Bioorg Med Chem Lett; 2016 May; 26(9):2188-93. PubMed ID: 27025343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and evaluation of novel nitrodihydroimidazooxazoles as promising anti-tuberculosis agents.
    Tao X; Gao C; Huang ZG; Luo W; Liu KL; Peng CT; Ding CZ; Li J; Chen SH; Yu LT
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2511-2515. PubMed ID: 31353295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.
    Vicente E; Villar R; Burguete A; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3321-6. PubMed ID: 18625764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinoxaline and quinoxaline-1,4-di-N-oxides: An emerging class of antimycobacterials.
    Keri RS; Pandule SS; Budagumpi S; Nagaraja BM
    Arch Pharm (Weinheim); 2018 May; 351(5):e1700325. PubMed ID: 29611626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective activity against Mycobacteriumtuberculosis of new quinoxaline 1,4-di-N-oxides.
    Vicente E; Pérez-Silanes S; Lima LM; Ancizu S; Burguete A; Solano B; Villar R; Aldana I; Monge A
    Bioorg Med Chem; 2009 Jan; 17(1):385-9. PubMed ID: 19058970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zanthoxylum capense constituents with antimycobacterial activity against Mycobacterium tuberculosis in vitro and ex vivo within human macrophages.
    Luo X; Pires D; Aínsa JA; Gracia B; Duarte N; Mulhovo S; Anes E; Ferreira MJ
    J Ethnopharmacol; 2013 Mar; 146(1):417-22. PubMed ID: 23337743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel aryloxy azolyl chalcones with potent activity against Mycobacterium tuberculosis H37Rv.
    Marrapu VK; Chaturvedi V; Singh S; Singh S; Sinha S; Bhandari K
    Eur J Med Chem; 2011 Sep; 46(9):4302-10. PubMed ID: 21764184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide derivatives as hits for the development of neglected disease drugs.
    Ancizu S; Moreno E; Torres E; Burguete A; Pérez-Silanes S; Benítez D; Villar R; Solano B; Marín A; Aldana I; Cerecetto H; González M; Monge A
    Molecules; 2009 Jun; 14(6):2256-72. PubMed ID: 19553897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.